Home
Newsletter
Events
Blogs
Reports
Graphics
RSS
About Us
Support
Write for Us
Media Info
Advertising Info
Health news

Procter & Gamble Surrenders Data to GAP Client (press release)

Wednesday, June 28, 2006 by: NewsTarget
Tags: health news, Natural News, nutrition


Most Viewed Articles
https://www.naturalnews.com/019484_drug_research_accountability.html
Delicious
diaspora
Print
Email
Share

Washington, D.C. -- Under pressure from Government Accountability Project (GAP) client Dr. Audrey Blumsohn, Proctor & Gamble finally (P&G) released the full research data set for its osteoporosis drug Actonel. Blumsohn had sought these data for four years. As Blumsohn anticipated, the data fail to support P&G's claim that Actonel is as effective as industry leaders in treating osteoporosis.

Blumsohn is currently on a North American speaking tour, presenting a series of lectures on scientific research integrity and spreading the word about his eventually successful, but overlong uphill battle against P&G. Earlier this week, Blumsohn spoke at the Harvard School of Public Health. Lectures to take place next week will be held at:

  • University of Toronto, Toronto, Canada. June 19, 2006.
  • Maine Medical Center, Portland, Maine. June 21, 2006.

In Maine, Blumsohn's lecture is entitled, "Where Are My Data? Learning from Ethical Crises at the University-Pharmaceutical Interface."

Blumsohn's story began in 2002, when he was contracted by P&G to study the effectiveness of Actonel by determining how the drug prevented bone fractures and its relation to change in bone resorption, the rate at which bone is removed. P&G hoped to prove that Actonel was more effective than its leading competitor, Merck's Fosamax, in strengthening bones and preventing fractures in post-menopausal women. As a senior faculty member at the University of Sheffield in the United Kingdom with research experience in skeletal disease, Blumsohn was fully qualified to evaluate Actonel's effectiveness.

From the onset of the study, Blumsohn was consistently denied access to P&G's "randomization codes" which are crucial in interpreting the data accrued in Blumsohn's study of Actonel. In order to avoid data manipulation by corporate drug companies, researchers are supposed to be granted access to full data sets in order to reach informed conclusions. Despite Blumsohn's refusal to draw conclusions from incomplete data sets, P&G began publishing articles and market reports under Blumsohn's name without his consent or approval, declaring the effectiveness of Actonel, and going as far to claim the drug's equivalence to Fosamax. From that point forward, Blumsohn has fought P&G for the release of the full data set, repeatedly demanding the removal of his name in the studies.

In February 2006, GAP's Food and Drug Safety Program stepped in to aid Blumsohn's cause, setting up meetings between Blumsohn and multiple congressional officials concerned with consumer safety and scientific integrity in order to raise awareness of this crucial issue. Due to mounting pressure and negative publicity, P&G launched a public relations campaign intended to salvage their reputation. The company first issued the researcher's "Bill of Rights," which stated researchers would have access to all information about which they are writing. Finally, in recent months, P&G released Actonel's full data sets to Blumsohn, a tremendous victory for Blumsohn and GAP. The full data sets verified Blumsohn's suspicions and provided evidence against P&G for scientific fraud.

"Blumsohn's tale illustrates the great need for accountability in the pharmaceutical industry, which puts a higher priority on profits than quality and safety," stated GAP Food and Drug Safety Director Mark Cohen. GAP continues to advocate the need for transparency in the pharmaceutical community in order to eliminate the practice of generating self-serving data to ensure the financial success of products.

For more information about any lecture, or to speak with Blumsohn or Cohen, please contact GAP Communications Director Dylan Blaylock at 202.408.0034 ext. 137, 202.236.3733 (cell)

Government Accountability Project

The Government Accountability Project is the nation's leading whistleblower protection organization. Through litigating whistleblower cases, publicizing concerns and developing legal reforms, GAP's mission is to protect the public interest by promoting government and corporate accountability. Founded in 1977, GAP is a non-profit, non-partisan advocacy organization with offices in Washington, D.C. and Seattle, WA.

###


Receive Our Free Email Newsletter

Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.


comments powered by Disqus



Natural News Wire (Sponsored Content)

Science.News
Science News & Studies
Medicine.News
Medicine News and Information
Food.News
Food News & Studies
Health.News
Health News & Studies
Herbs.News
Herbs News & Information
Pollution.News
Pollution News & Studies
Cancer.News
Cancer News & Studies
Climate.News
Climate News & Studies
Survival.News
Survival News & Information
Gear.News
Gear News & Information
Glitch.News
News covering technology, stocks, hackers, and more